Prognostic factors associated with non-remission and low disease activity status af ter one year of psoriatic arthritis patients treatment in real practice

Background. Remission/low disease activity (LDA) are acceptable goal of psoriatic arthritis (PsA) treatment. Prognostic factors for non-remission/LDA hasn’t been fully studied yet and data is limited.
The aim – to determine the prognostic factors associated with non-remission/LDA status within 1 year of treatment in PsA pts in real practice. Methods. 292 pts (M/F=122/170) with active PsA fulfilling the CASPAR criteria were included. Mean age 46.1±12.5 years (yrs), PsA duration 10.4±7.1 months (mos), psoriasis (Ps) duration 19.32±12.08 mos, body mass index (BMI) 27.7±5.6 kg/m² , median (Me) of DAPSA – 23.8 [14.7; 37.4]. 182 pts was given therapy with synthetic (s) DMARDs predominantly methotrexate (MTX), 110 pts – bDMARDs as monotherapy or with combination with MTX or other sDMARDs. At baseline (BL) and at 1 year of therapy PsA activity by tender/swelling joint count (TJC)/68, (SJC)/66, pain (VAS), Patient global assessment disease activity (PtGA, VAS), CRP (mg/l), dactylitis, enthesitis by LEI and plantar fascia, BSA (%), HAQ, DAPSA were evaluated. DAPSA>28 indicate high disease activity (HDA), DAPSA=15–28 – moderate activity (MoDA), DAPSA=5–14 – LDA, DAPSA≤4 – remission. By 1 year of therapy the proportion of pts who had not reached remission or LDA were calculated. The one-factor model of logistic regression was used to identify a group of features that are associated with remission or LDA  nonachievement. M±SD, Me [Q25; Q75], Min–Max, %, t-test, Peаrson χ² , Mann – Whitney tests, ORs with 95% CI were performed. All p<0.05, were considered to indicate statistical significance.
Results. At 1 year of therapy 116 pts of 292 (40%) have HDA/MoDA by DAPSA. Remission/LDA was reached in 176 (60%) pts, 110 of them (62.5%) were treated with bDMARDs. Comparative analysis in both groups and one-factor model of logistic regression showed the following features at BL were associated with non-remission/LDA status: TJC>5 (p<0.001), SJC>3 (p<0.001), CRP>10 mg/l (p<0.001), HAQ>0.5 (p<0.001), presence of enthesitis (p<0.001), dactylitis (p<0.001), BMI>30 (p<0.002) and had to be treated with sDMARDs. PsA pts with combination of these clinical features at first visit have a higher risk of not achieving remission/LDA status in comparison to PsA pts without them, OR with 95% CI.
Conclusion. In real practice remission/LDA cannot achieve 40% PsA pts despite going through therapy. It is a combination of clinical fea tures at BL – TJC>3, SJC>5, CRP>10 mg/l, HAQ>0.5, presence of enthesitis, dactylitis, BMI>30 kg/m² and sDMARDs monotherapy – that constitutesa prognostic factor with negative impact on achievement remission/LDA after 1 year of treatment.

1. Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;378(10):957-970. doi: 10.1056/NEJMra1505557

2. Coates LC, Soriano ER, Corp N, Bertheussen H, Callis Duffin K, Campanholo CB, et al.; GRAPPA Treatment Recommendations domain subcommittees. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): Updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18(8):465-479. doi: 10.1038/s41584-022-00798-0

3. Kavanaugh A, Helliwell P, Ritchlin CT. Psoriatic arthritis and burden of disease: Patient perspectives from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey. Rheumatol Ther. 2016;3(1):91-102. doi: 10.1007/s40744-016-0029-z

4. de Vlam K, Steinfeld S, Toukap AN, van den Bosch F, Joos R, Geysens P, et al.; BEPAS Study Investigators. The burden of psoriatic arthritis in the biologics era: Data from the Belgian Epidemiological Psoriatic Arthritis Study. Rheumatology (Oxford). 2021;60(12):5677-5685. doi: 10.1093/rheumatology/keab233

5. Zardin-Moraes M, da Silva ALFA, Saldanha C, Kohem CL, Coates LC, Henrique LR, et al. Prevalence of psoriatic arthritis patients achieving minimal disease activity in real-world studies and randomized clinical trials: Systematic review with metaanalysis. J Rheumatol. 2020;47(6):839-846. doi: 10.3899/jrheum.190677

6. Ng BCK, Jadon DR. Unmet needs in psoriatic arthritis. Best Pract Res Clin Rheumatol. 2021;35(2):101693. doi: 10.1016/j.berh.2021.101693

7. Tucker LJ, Coates LC, Helliwell PS. Assessing disease activity in psoriatic arthritis: A literature review. Rheumatol Ther. 2019;6:23-32. doi: 1007/s40744-018-0132-4

8. Hutton J, Mease P, Jadon D. Horizon scan: State-of-the-art therapeutics for psoriatic arthritis. Best Practice Res Clin Rheumatol. 2022;36:101809. doi: 10.1016/j.berh.2022.101809

9. Lubrano E, Perrotta FM, Scriffignano S, Coates LC, Helliwell P. Sustained very low disease activity and remission in psoriatic arthritis patients. Rheumatol Ther. 2019;6:521-528. doi: 10.1007/s40744-019-00171-w

10. Murray K, Turk M, Alammari Y, Young F, Gallagher P, Saber T, et al. Long-term remission and biologic persistence rates: 12-year real-world data. Arthritis Res Ther. 2021;23(1):25. doi: 10.1186/s13075-020-02380-z

11. Alten R, Conaghan PG, Strand V, Sullivan E, Blackburn S, Tian H, et al. Unmet needs in psoriatic arthritis patients receiving immunomodulatory therapy: Results from a large multinational real-world study. Clin Rheumatol. 2019;38(6):1615-1626. doi: 10.1007/s10067-019-04446-z

12. Hagège B, Tan E, Gayraud M, Fautrel B, Gossec L, Mitrovic S. Remission and low disease activity in psoriatic arthritis publications: A systematic literature review with meta-analysis. MetaAnalysis Rheumatology (Oxford). 2020;59(8):1818-1825. doi: 10.1093/rheumatology/keaa030

13. Haugeberg G, Michelsen B, Tengesda S, Hansen IJW, Diamantopoulos A, Kavanaugh A. Ten years of follow-up data in psoriatic arthritis: Results based on standardized monitoring of patients in an ordinary outpatient clinic in southern Norway. Arthritis Res Ther. 2018;20:160. doi: 10.1186/s13075-018-1659-z

14. Sundanum S, Orr C, Veale D. Targeted therapies in psoriatic arthritis – An update. Int J Mol Sci. 2023;24:6384. doi: 10.3390/ijms24076384

15. Alharbi S, Ye JY, Lee K-A, Chandran V, Cook RJ, Gladman DD. Remission in psoriatic arthritis: Definition and predictors. Semin Arthritis Rheum. 2020;50(6):1494-1499. doi: 10.1016/j.semarthrit.2020.01.012

16. Vallejo-Yagüe E, Burkard T, Micheroli R, Burden AM. Minimal disease activity and remission in patients with psoriatic arthritis with elevated body mass index: An observational cohort study in the Swiss Clinical Quality Management cohort. BMJ Open. 2022;12:e061474. doi: 10.1136/bmjopen-2022-061474.

17. Almodóvar R, Zarco P, Otón T, Carmona L. Effect of weight loss on activity in psoriatic arthritis: A systematic review. Review Reumatol Clin (Engl Ed). 2018;14(4):207-210. doi: 10.1016/j.reuma.2017.01.010

18. Korsakova YL, Korotaeva TV, Loginova EI, Gubar EE, Vasilenko EA, Vasilenko AA, et al. The relationship between obesity, cardiometabolic disorders and disease activity in psoriatic arthritis patients: Data from the Russian register. Terapevticheskii arkhiv. 2021;93(5):573-580 (In Russ.). doi: 10.26442/00403660.2021.05.200789

19. Lubrano Е, Scriffignano S, Perrotta FM. Residual disease activity and associated factors in psoriatic arthritis. J Rheumatol. 2020;47:1490-1495. doi: 10.3899/jrheum.190679

20. Coates LC, Wit M, Buchanan-Hughes A, Smulders M, Sheahan A, Ogdie AR. Residual disease associated with suboptimal treatment response in patients with psoriatic arthritis: A systematic review of real-world evidence. Rheumatol Ther. 2022;9:803-821. doi: 10.1007/s40744-022-00443-y

21. Lubrano E, Scriffignano S, Perrotta FM. Sequencing of biologic and target synthetic disease modifying anti-rheumatic drugs in psoriatic arthritis: Are we ready to redefine the treatment strategy? A Perspective Rheumatol Ther. 2023;10:301-306. doi: 10.1007/s40744-022-00514-0